Navidea biopharmaceuticals, inc. announces distribution of series k preferred stock to holders of its common stock

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its board of directors declared a dividend of one one-thousandth of a share of newly designated series k preferred stock, par value $0.001 per share, for each outstanding share of the company's common stock held of record as of 5:00 p.m. eastern time on june 27, 2.
NAVB Ratings Summary
NAVB Quant Ranking